P/E ratio for Nectar Lifesciences (NECLIFE.NS)
P/E ratio as of July 2025 (TTM): 20.0
According to Nectar Lifesciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 19.9517. At the end of 2024 the company had a P/E ratio of 156.
P/E ratio history for Nectar Lifesciences from 2018 to 2024
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | 156 | -1220.91% |
| 2023 | -13.9 | -163.23% |
| 2022 | 22.0 | -476.04% |
| 2021 | -5.84 | -187.31% |
| 2020 | 6.69 | -19.41% |
| 2019 | 8.30 | -30.79% |
| 2018 | 12.0 | -16.18% |
| 2017 | 14.3 | -6.77% |
| 2016 | 15.4 | 26.15% |
| 2015 | 12.2 | 44.99% |
| 2014 | 8.39 | 97.31% |
| 2013 | 4.25 | -42.58% |
| 2012 | 7.41 | 43.23% |
| 2011 | 5.17 | -17.61% |
| 2010 | 6.28 | 95.37% |
| 2009 | 3.21 | -19.38% |
| 2008 | 3.99 | -15.67% |
| 2007 | 4.73 | -48.69% |
| 2006 | 9.21 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.